The effect of l-arginine supplementation and surgical trauma on the frequency of myeloid-derived suppressor cells and T lymphocytes in tumour and blood of colorectal cancer patients

2022 ◽  
Vol 67 (1) ◽  
pp. 66-78
Author(s):  
Jarosław Szefel ◽  
Tomasz Ślebioda ◽  
Jakub Walczak ◽  
Wiesław Janusz Kruszewski ◽  
Mariusz Szajewski ◽  
...  
Author(s):  
IBRAHIM A. ALTEMEMI ◽  
OSAMAH ABD ALI NASSR

The current study was focused on patients with Colorectal Cancer between the ages of (26–82years). The objective of this study to determine the IL-17 level and CD33 expression status in patients with Colorectal Cancer. A total 60 of (40 patients and 20 control groups) were collected from Gastroenterology and Liver diseases teaching hospital from March 2018 to the end of May 2018 Iraq. The results show Median IL-17 was significantly higher in study group than in control group (p less than 0.001), 12.13 (9.73) pg/ml versus 0.41 (0.67) pg/ml, and Median CD33 was significantly higher in study group than in control group (p less than 0.001), 73.00 (5.0) % versus 4.50 (3.75) %.


2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e22121-e22121 ◽  
Author(s):  
Simon Pernot ◽  
Magali Terme ◽  
Elie Marcheteau ◽  
Thibault Voron ◽  
Orianne Colussi ◽  
...  

e22121 Background: Tumors develop immunosuppressive mechanisms to escape the immune system. Among these mechanisms, T lymphocytes can express inhibitory molecules such as Program Death-1 (PD-1) protein which impair their activation and their effector functions. Multi-target anti-angiogenic tyrosine kinase inhibitors (TKI) that are routinely used as first- or second-line treatment of cancer patients, have been shown to modulate immunosuppressive mechanisms especially regulatory T cells. However, the role of specific VEGF/VEGFR blockade on PD-1 expression by T lymphocytes has not been studied. Methods: PD-1 expression on T lymphocytes has been analyzed by flow cytometry in a mouse model of colorectal cancer (CT26) treated by anti-angiogenic molecules targeting the VEGF-A/VEGFR axis and in the peripheral blood of metastatic colorectal cancer patients. Results: Sunitinib that directly targets VEGFR, PDGFR, c-kit, but also anti-VEGF-A antibody (the mouse orthologue of bevacizumab) decrease PD-1 expression on T lymphocytes infiltrating the tumors. Interestingly, anti-angiogenic treatments decrease the percentage of lymphocytes expressing not only PD-1 but also Tim-3 suggesting that the most exhausted T cells are targeted by anti-angiogenic treatments. Administration of masitinib, a TKI acting on KIT, PDGFR and FAK but not on the VEGF/VEGF-R pathway, was not able to modulate PD-1 expression on T cells. Finally, anti-VEGF-A treatment (bevacizumab) associated with chemotherapy decreases the proportion of PD-1+ CD4+T cells in the peripheral blood of metastatic colorectal cancer patients. Conclusions: These results show that anti-angiogenic treatments targeting VEGFA/VEGFR decrease PD-1-expressing T lymphocytes in colorectal cancer. These results suggest that VEGF-A could be involved in PD-1 expression and maybe in the induction of T lymphocyte exhaustion in colorectal cancer. We and others have shown that anti-angiogenic molecules could modulate other immunosuppressive populations such as regulatory T cells and myeloid suppressive cells, anti-angiogenic molecules might be efficiently associated with immunotherapeutic strategies in colorectal cancer.


2014 ◽  
Vol 2 (4) ◽  
pp. 505-508 ◽  
Author(s):  
BASKAR SUBRAMANI ◽  
CHITHRA RAMANATHAN PULLAI ◽  
KOHILA KRISHNAN ◽  
SHEELA DEVI SUGADAN ◽  
XUEWEN DENG ◽  
...  

2018 ◽  
Vol 37 (11) ◽  
pp. 1015-1024
Author(s):  
Fabiola Müller ◽  
Marrit A. Tuinman ◽  
Ellen Stephenson ◽  
Ans Smink ◽  
Anita DeLongis ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document